Literature DB >> 30037666

Protective efficacy of monovalent and trivalent recombinant MVA-based vaccines against three encephalitic alphaviruses.

Wei-Gang Hu1, Robin Steigerwald2, Marcus Kalla2, Ariane Volkmann2, David Noll3, Les P Nagata4.   

Abstract

The three encephalitic alphaviruses, western, eastern, and Venezuelan equine encephalitis viruses (WEEV, EEEV, and VEEV) are potential biothreat agents due to high infectivity through aerosol exposure, ease of production in large amounts, and relative stability in the environment. Currently, there is no licensed vaccine for human use to these three encephalitic alphaviruses, and efforts to move vaccine candidates forward into clinical trials have not been successful. In this study, the modified vaccinia Ankara-Bavarian Nordic (MVA-BN®) vaccine platform was used to construct and produce three monovalent recombinant MVA-BN-based encephalitic alphavirus vaccines, MVA-BN-W, MVA-BN-E, and MVA-BN-V. Additionally, a MVA-BN-based construct was designed to produce antigens against all three alphaviruses, the trivalent vaccine MVA-BN-WEV. The protective efficacy of these vaccines was evaluated in vivo. Female BALB/c mice were immunized with two doses of each monovalent MVA-BN-based alphavirus vaccine, a mixture of the three monovalent vaccines, MVA-BN-W + E + V, or the trivalent vaccine MVA-BN-WEV at a four-week interval. Two weeks after the booster immunization, the mice were instilled intranasally with 5 × 103 to 1 × 104 plaque forming units of WEEV, EEEV, or VEEV. All mice immunized with monovalent vaccines survived the respective virus challenge without any signs of illness or weight loss, while all the control mice died. The triple mixture of vaccines or the trivalent vaccine also provided 90 to 100% protection to the mice against WEEV and VEEV challenges, and 60% to 90% protection against EEEV challenge. These data suggest that each monovalent MVA-BN-W, MVA-BN-E, and MVA-BN-V is a potential vaccine candidate against respective encephalitic alphavirus and the three monovalent vaccines can be given in a mixture (MVA-BN-W + E + V) or the trivalent vaccine MVA-BN-WEV can serve as a true multivalent vaccine without significantly reducing efficacy against WEEV and VEEV despite slightly reduced efficacy against EEEV challenge. Crown
Copyright © 2018. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Encephalitic alphaviruses; MVA-BN; Mixture of vaccines; Monovalent; Protective efficacy; Trivalent; Vaccines

Mesh:

Substances:

Year:  2018        PMID: 30037666     DOI: 10.1016/j.vaccine.2018.06.064

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

Review 1.  Insights into Antibody-Mediated Alphavirus Immunity and Vaccine Development Landscape.

Authors:  Anthony Torres-Ruesta; Rhonda Sin-Ling Chee; Lisa F P Ng
Journal:  Microorganisms       Date:  2021-04-22

2.  Aerosol infection of Balb/c mice with eastern equine encephalitis virus; susceptibility and lethality.

Authors:  Amanda L Phelps; Lyn M O'Brien; Lin S Eastaugh; Carwyn Davies; Mark S Lever; Jane Ennis; Larry Zeitlin; Alejandro Nunez; David O Ulaeto
Journal:  Virol J       Date:  2019-01-05       Impact factor: 4.099

Review 3.  Current Understanding of the Molecular Basis of Venezuelan Equine Encephalitis Virus Pathogenesis and Vaccine Development.

Authors:  Anuj Sharma; Barbara Knollmann-Ritschel
Journal:  Viruses       Date:  2019-02-18       Impact factor: 5.048

4.  A Monovalent and Trivalent MVA-Based Vaccine Completely Protects Mice Against Lethal Venezuelan, Western, and Eastern Equine Encephalitis Virus Aerosol Challenge.

Authors:  Lisa Henning; Kathrin Endt; Robin Steigerwald; Michael Anderson; Ariane Volkmann
Journal:  Front Immunol       Date:  2021-01-19       Impact factor: 7.561

5.  Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection.

Authors:  Stephen Boulton; Joanna Poutou; Nikolas T Martin; Taha Azad; Ragunath Singaravelu; Mathieu J F Crupi; Taylor Jamieson; Xiaohong He; Ricardo Marius; Julia Petryk; Christiano Tanese de Souza; Bradley Austin; Zaid Taha; Jack Whelan; Sarwat T Khan; Adrian Pelin; Reza Rezaei; Abera Surendran; Sarah Tucker; Emily E F Brown; Jaahnavi Dave; Jean-Simon Diallo; Rebecca Auer; Jonathan B Angel; D William Cameron; Jean-Francois Cailhier; Réjean Lapointe; Kyle Potts; Douglas J Mahoney; John C Bell; Carolina S Ilkow
Journal:  Mol Ther       Date:  2021-10-20       Impact factor: 12.910

6.  Sequestration of Late Antigens Within Viral Factories Impairs MVA Vector-Induced Protective Memory CTL Responses.

Authors:  Sha Tao; Ronny Tao; Dirk H Busch; Marek Widera; Heiner Schaal; Ingo Drexler
Journal:  Front Immunol       Date:  2019-12-04       Impact factor: 7.561

7.  The Western Equine Encephalitis Lyophilized, Inactivated Vaccine: An Update on Safety and Immunogenicity.

Authors:  Maryam Keshtkar-Jahromi; Ronald B Reisler; Jeannine M Haller; Denise P Clizbe; Robert G Rivard; Anthony P Cardile; Benjamin C Pierson; Sarah Norris; David Saunders; Phillip R Pittman
Journal:  Front Immunol       Date:  2020-11-09       Impact factor: 7.561

Review 8.  Vaccinia-based vaccines to biothreat and emerging viruses.

Authors:  Les P Nagata; Chad R Irwin; Wei-Gang Hu; David H Evans
Journal:  Biotechnol Genet Eng Rev       Date:  2018-05-21       Impact factor: 4.200

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.